Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India
Fitusiran is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents aged 12 years and older, with or without factor VIII or IX inhibitors The post CDSCO approves Sanofi’s Qfitlia for haemophilia A and B in India appeared first on Express Pharma.
Read Full Article
Express Pharma
Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing
The partnership will cover technology transfer, clinical manufacturing and commercial production of VeGen Bio’s VL-2511 in India The post Nucelion Therapeutics, VeGen Bio collaborate on CAR-T cell therapy manufacturing appeared first on Express Pharma.
Read Full Article
Pharma Tech
AbbVie races into F1 as pharma companies continue push into sport
AbbVie is just one of several pharmaceutical companies to pen sponsorship deals in sport, blurring the commercial line between the two industries.
Read Full Article
Express Pharma
Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International
On the sidelines of the Bengaluru Pharma Summit, Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International, speaks with Neha Aathavale, Correspondent, Express Pharma […] The post Exclusive Interview with Dr. Villoo Morawala Patell, Founder & Chairperson of Avesthagen Limited and The Avestagenome Project® International appeared first on Express Pharma.
Read Full Article
Pharma Tech
Pharma’s supplier sprawl problem: When more vendors create less control
Consolidating complicated supply chains with trusted providers reduces governance, sharpens cost and emissions insight, and creates a more resilient, coordinated network.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 21, 2026, 12:25 PM
EMA Marketing Authorization of New Drugs in September 2026
Shots: NewAmsterdam and Menarini Report the EC Approval for Ubeslo and Evlarco for Primary Hypercholesterolemia Company: NewAmsterdam and Menarini Product: Ubeslo and Evlarco Active Ingredient: Obicetrapib and Obicetrapib + Ezetimibe FDC Disease: Primary Hypercholesterolemia Date: Sep 21, 2026 Shots: Editor’s Take: Beyond the Headlines The EC approvals of Ubeslo and Evlarco give NewAmsterdam and Menarini… The post EMA Marketing Authorization of New Drugs in September 2026 appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:30 AM
Rapport Therapeutics Reports Topline P-II Trial Results on RAP-219 in Bipolar Mania
Shots: Ref: Rapport | Image: Rapport | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Rapport Therapeutics Reports Topline P-II Trial Results on RAP-219 in Bipolar Mania appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:28 AM
Takeda Reports P-IV (VERDICT) Treat-to-Target Trial Data of Entyvio (Vedolizumab) for Ulcerative Colitis at UEGW 2026
Shots: Takeda has reported data from the randomized P-IV (VERDICT) treat-to-target trial, conducted by Alimentiv in collaboration with Takeda, evaluating IV Entyvio (vedolizumab) in adults (N=672) with moderate to severe ulcerative colitis (UC) randomized to 3 increasingly stringent corticosteroid-free (CSF) targets: symptomatic remission (Group 1), symptomatic + endoscopic remission (Group 2), or disease clearance (symptomatic… The post Takeda Reports P-IV (VERDICT) Treat-to-Target Trial Data of Entyvio (Vedolizumab) for Ulcerative Colitis at UEGW 2026 appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
TISSIUM Receives CE Mark for Eclipsium to Enable Atraumatic Mesh Fixation in Ventral Hernia Repair
Shots: Ref: GlobeNewswire | Image: TISSIUM | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post TISSIUM Receives CE Mark for Eclipsium to Enable Atraumatic Mesh Fixation in Ventral Hernia Repair appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
Lumen Bioscience Reports P-II (RePreve) Trial Results of LMN-201 for C. difficile Infection
Shots: Lumen Bioscience has reported results from the P-II (RePreve) trial evaluating oral LMN-201 vs PBO, given during & after SoC antibiotics, in pts (N=45; Part A: 22, Part B: 23) with C. difficile infection (CDI); Part B was a 1:1 randomized, double-blind, PBO-controlled cohort In Part B, global cure was achieved in 83.3% (10/12)… The post Lumen Bioscience Reports P-II (RePreve) Trial Results of LMN-201 for C. difficile Infection appeared first on PharmaShots.
PharmaShots
Oct 21, 2026, 11:21 AM
Shionogi and F2G Report P-III (OASIS) Trial Data of Olorofim for Invasive Aspergillosis
Shots: Shionogi & F2G have reported data from the global, adjudicator-blinded P-III (OASIS) trial evaluating oral olorofim (150mg, BID on Day 1, then 90mg, BID; up to 84 days) vs IV AmBisome (3mg/kg, QD) followed by SoC in adults (N=225; 2:1) with invasive aspergillosis for whom mould-active azole therapy was inappropriate or ineffective; data will… The post Shionogi and F2G Report P-III (OASIS) Trial Data of Olorofim for Invasive Aspergillosis appeared first on PharmaShots.
News
Latest industry coverage
Google News
Oct 21, 2026, 9:03 PM
Once-Monthly Injections for Schizophrenia, Dementia Gain Approval - 조선일보
Once-Monthly Injections for Schizophrenia, Dementia Gain Approval 조선일보
Google News
Oct 21, 2026, 8:14 PM
Eppendorf and BioLabs expand collaboration to support biotech innovation in Munich - Cambridge Network
Eppendorf and BioLabs expand collaboration to support biotech innovation in Munich Cambridge Network
Google News
Oct 21, 2026, 8:10 PM
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 - Wed, 10/21/2026 - 16:10 - Helus Pharma
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 - Wed, 10/21/2026 - 16:10 Helus Pharma
Google News
Oct 21, 2026, 8:10 PM
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 - GlobeNewswire
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 GlobeNewswire
Google News
Oct 21, 2026, 8:08 PM
AHA urges court to reject drug industry intervention in 340B rebate program case - American Hospital Association
AHA urges court to reject drug industry intervention in 340B rebate program case American Hospital Association
Google News
Oct 21, 2026, 8:01 PM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences Business Wire
Google News
Oct 21, 2026, 7:39 PM
PharmTech AI Pulse Check: New Approach Methodologies Demand New QC Skills - PharmTech.com
PharmTech AI Pulse Check: New Approach Methodologies Demand New QC Skills PharmTech.com
Google News
Oct 21, 2026, 7:14 PM
Eppendorf, BioLabs Expand Collaboration to New Munich Site - Contract Pharma
Eppendorf, BioLabs Expand Collaboration to New Munich Site Contract Pharma
Google News
Oct 21, 2026, 7:12 PM
Advancing Pharmacy, Celebrating Impact: Meet the 2026 College of Pharmacy Award Recipients - The University of Texas at Austin
Advancing Pharmacy, Celebrating Impact: Meet the 2026 College of Pharmacy Award Recipients The University of Texas at Austin
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer